Injection Pen Market. The global injection pen market is on track for substantial growth, with a forecasted compound annual ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

The therapy’s main competitor in the space is Sanofi and Regeneron’s Dupixent (dupilumab). It has been approved to treat CRSwCP and multiple immune-mediated disorders, including asthma and COPD. In ...

The therapy’s main competitor in the space is Sanofi and Regeneron’s Dupixent (dupilumab). It has been approved to treat CRSwCP along with multiple immune-mediated disorders including asthma and COPD.

Get detailed information on Dupilumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with eosinophilic esophagitis, expanding its market potential ...

The EMA’s decision marks an expansion from the initial EU approval for EoE treatment in adolescents and adults. Credit: Orawan Pattarawimonchai/Shutterstock. The ...

Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up ...

Dupixent is also approved in this young age ... to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron ...

such as Dupixent for the treatment of chronic pruritus of unknown origin, bullous pemphigoid, and other potential indications; the ability of Regeneron’s collaborators, licensees, suppliers, or other ...

TARRYTOWN, N.Y. and PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent ...